Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Embody Post-Market Clinical Follow-Up Study

NCT: NCT05735119 · ACTIVE_NOT_RECRUITING

NCT IDNCT05735119
StatusACTIVE_NOT_RECRUITING
Start Date2022-11-09
Completion2028-06

Brief Summary

A multi-center, prospective post-market clinical follow-up study: subscapularis repair augmented with Tapestry Biointegrative Implant after shoulder arthroplasty. The primary objective of this study is to evaluate the long-term integrity of the subscapularis tendon repair after shoulder arthroplasty augmented with Tapestry Biointegrative Implant, assessed by ultrasound 6 months postoperatively. Secondary objectives are to assess shoulder function (internal rotation strength), safety, and patient reported outcomes. Patients will be evaluated preoperatively, at the time of surgery, 3, 6, 12 and 24 months after surgery.

Frequently Asked Questions

What is Embody Post-Market Clinical Follow-Up Study?

Embody Post-Market Clinical Follow-Up Study is a clinical trial registered under NCT05735119. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT05735119?

The current status of NCT05735119 (Embody Post-Market Clinical Follow-Up Study) is: ACTIVE_NOT_RECRUITING.

When did Embody Post-Market Clinical Follow-Up Study start?

Embody Post-Market Clinical Follow-Up Study started on 2022-11-09.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.